CAROLYN FREEMAN: Open Payments
NPI 1326078973 · DRESDEN, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,213 in 123 payments from 13 companies in 2025. Trend: 2023 $1,067 · 2024 $1,324 · 2025 $2,213
Food & beverage: $2,213
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 27 | $433 |
| Neurocrine BioSciences, Inc. | 18 | $349 |
| Alkermes, Inc. | 14 | $326 |
| ABBVIE INC. | 19 | $226 |
| Janssen Pharmaceuticals, Inc | 8 | $161 |
| Vanda Pharmaceuticals Inc. | 5 | $146 |
| Otsuka America Pharmaceutical, Inc. | 11 | $143 |
| Lundbeck LLC | 6 | $136 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $118 |
| Axsome Therapeutics, Inc. | 5 | $98 |
Products named: CAPLYTA, INGREZZA, ARISTADA, VRAYLAR, REXULTI, INVEGA SUSTENNA, TRINTELLIX, HETLIOZ.
Industry payments across TN — which companies pay providers there.
